目的：探讨血清β葡萄糖醛酸酶（βＧ）活性测定对肝脏肿瘤的临床意义。方法：建立ＥＬＩＳＡ技术测定肝癌与不同疾病患者血清中βＧ活性，并对肝癌患者治疗前后血清βＧ活性变化规律进行研究。结果：肝癌患者血清中βＧ活性明显高于肺癌，胃癌，甲状腺癌；也明显高于肝血管瘤，肝硬化等肝脏良性病变，均为Ｐ＜００１；肝癌患者手术切除治疗及介入治疗后血清βＧ活性明显降低，Ｐ＜００１；而肝癌复发时βＧ活性又有增高趋势。结论：作为一种体内酶标志，βＧ对肝癌的诊断、治疗及预后判定有一定的参考价值 Objective: To explore the clinical significance of serum βglucuronidase (βG) activity assay in liver tumors. Methods: The serum β-G activity in liver cancer patients and patients with different diseases was determined by ELISA. The changes of serum β-G activity before and after treatment of liver cancer patients were studied. RESULTS: The serum β-G activity of liver cancer patients was significantly higher than that of lung cancer, gastric cancer and thyroid cancer. It was also significantly higher than hepatic hemangiomas, liver cirrhosis and other benign liver diseases. All patients were P<0.01; surgical resection and intervention of liver cancer patients After treatment, serum β-G activity decreased significantly, P <0  01; while liver cancer recurrence, β  G activity increased again. Conclusion: As an in vivo enzyme marker, βG has a certain reference value for the diagnosis, treatment and prognosis of liver cancer.